New Med for Severe Mental Illness Tied to Less Weight Gain

Olanzapine plus samidorphan (Lybalvi) vs olanzapine alone is associated with less weight gain while achieving similar clinical outcomes in patients with recent-onset severe mental illness, new research suggests. However, least one expert says the weight difference between the two drugs is of “questionable clinical benefit.” Last year, the US Food and Drug Administration (FDA) approved … Read more

New Tool Cuts CVD Risk in Patients With Serious Mental Illness

A clinical decision support (CDS) system that can be implemented in primary care reduces cardiovascular risk factors (CV) common in patients with serious mental illness (SMI), new research suggests. Investigators assessed more than 70 primary care clinics that treated close to 9000 patients with SMI. Disorders included schizophrenia, bipolar disorder, and schizoaffective disorder. The clinics … Read more